Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review
Robert Foerster,Robert Foerster,Daniel R. Zwahlen,Daniel R. Zwahlen,Andre Buchali,Hongjian Tang,Christina Schroeder,Christina Schroeder,Paul Windisch,Erwin Vu,Sati Akbaba,Tilman Bostel,Tanja Sprave,Constantinos Zamboglou,Thomas Zilli,Jean-Jacques Stelmes,Tejshri Telkhade,Vedang Murthy +17 more
TL;DR: In this article, the authors conducted a systematic review to analyze the available data on observed toxicities, ADT prescription practice, and oncological outcome to shed more light on the value of Stereotactic body radiotherapy (SBRT) in localized prostate cancer (PCA).
Journal ArticleDOI
Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
David Pasquier,Philippe Nickers,Didier Peiffert,Philippe Maingon,Pascal Pommier,Thomas Lacornerie,Geoffrey Martinage,Emmanuelle Tresch,Eric Lartigau +8 more
TL;DR: Hypofractionated stereotactic boost is effective and safely delivered for intermediate-risk prostate carcinoma after conventional radiation and Mild-term relapse-free survival and tolerance results are promising, and further follow-up is warranted to confirm the results at long term.
Journal ArticleDOI
TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol.
Jarad Martin,Paul J. Keall,Shankar Siva,Peter B. Greer,David R. H. Christie,Kevin L. Moore,Jason Dowling,David Pryor,Peter Chong,Nicholas McLeod,Avi Raman,James Lynam,Joanne Smart,Christopher Oldmeadow,Colin Tang,Declan G. Murphy,Jeremy Millar,Keen Hun Tai,Lois Holloway,Penny Reeves,Amy Hayden,Tee Lim,Tanya Holt,Mark Sidhom +23 more
TL;DR: NINJA is a multicentre cooperative clinical trial comparing two SBRT regimens for efficacy with technical substudies focussing on MRI only planning and the use of knowledge-based planning (KBP) to assess radiotherapy plan quality.
Journal ArticleDOI
Noncoplanar Beam Angle Class Solutions to Replace Time-Consuming Patient-Specific Beam Angle Optimization in Robotic Prostate Stereotactic Body Radiation Therapy.
TL;DR: A recipe for creation of robust beam angle CSs for robotic prostate stereotactic body radiation therapy has been developed and the use of a CS instead of iBAS reduced the computation time by a factor of 14 to 25, mainly depending on beam number, without loss in plan quality.
Journal ArticleDOI
Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.
Frank Wolf,Felix Sedlmayer,Daniel M. Aebersold,Clemens Albrecht,Dirk Böhmer,Michael Flentje,Ute Ganswindt,Pirus Ghadjar,Stefan Höcht,Tobias Hölscher,Arndt-Christian Müller,Peter Niehoff,Michael Pinkawa,Nina-Sophie Schmidt-Hegemann,Constantinos Zamboglou,Daniel Zips,Thomas Wiegel +16 more
TL;DR: An overall assessment of the level of evidence is made, recommendations and requirements that should be followed before introducing ultrahypofractionation into routine clinical use are provided, and a brief overview of the current evidence is given.
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more